The size of the Genetic Testing Market in the Middle East & Africa was worth USD 3.45 million in 2020 and is estimated to reach USD 4.76 Million by 2025, growing at a CAGR of 6.64% during the forecast period.
Currently, genetic testing is the most attractive market among the different segments of molecular diagnostics as the need for providing better healthcare is growing. It is the most sophisticated form of medical testing where even the slightest modification in chromosomes, genes, or proteins which are associated with inherited disease conditions are identified.
Genetic testing is the study of DNA to predict the susceptibility of diseases, its diagnosis, or determine the likely course of a disease. Genetic testing has led to an easy diagnosis of diseases, such as sickle cell anemia, hemophilia, and cystic fibrosis, helping many patients living a normal life.
The primary reasons for the growth of the genetic testing market are attributed to the growing awareness among the individuals about the benefits and the potential it has. Some other drivers that aid in the growth of the genetic testing market is, new innovations in the genetic testing space, an increase in the aging population, the rise in the number of chronic disease cases, and rising incidences of cancer cases.
However, there are few hurdles that hinder the growth of the market like, the high costs associated with genetic testing being one. There are concerns among the individuals regarding the authenticity of genetic reports due to the credibility of standard procedure.
Genetic testing for cancer is predicted to have a high growth rate and is likely to lead the genetic testing market in the near future. The market for new-borns screening, rare and fatal disorders diagnosing and estimating the probability of occurrence of diseases is expected to expand. Particularly, genetic tests to screen the new-borns are likely to expand immensely over the coming years.
New opportunities for genetic and its related applications are likely to grow owing to the increasing incidences of genetic diseases. The transformation from being a service-driven market to a product-driven market is anticipated to provide a push to the diagnostic companies for the expansion of their operations.
This report has been segmented and sub-segmented into the following categories.
Key participants in the MEA Genetic Testing Market profiled in this report are Abbott Laboratories, Roche Molecular Diagnostics Inc., Abbott Molecular Inc., AutoGenomics Inc., Celera Group, ELITech Group, BioRad Laboratories, PerkinElmer Inc., Quest Diagnostics Inc., Transgenomic Inc. and Applied Biosystems Inc.,
This report comes with
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Analysis Design
2.3 Research Phases
2.3.1 Secondary Research
2.3.2 Primary Research
2.3.3 Econometric Modelling
2.3.4 Expert Validation
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type
5.1.1 Carrier Testing
5.1.2 Diagnostic Testing
5.1.3 Prenatal Testing
5.1.4 Neonatal Testing
5.2 By Application
5.2.1 Cancer Testing
5.2.2 Prenatal Testing
5.2.3 Pharmacogenomics Testing
5.2.4 Presdisposition Testing
6. Geographical Analysis
6.1 Introduction
6.2 Middle East
6.3 Africa
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Roche Molecular Diagnostics Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Abbott Laboratories
8.3 AutoGenomics Inc.
8.4 Celera Group
8.5 ELITech Group
8.6 BioRad Laboratories
8.7 Quest Diagnostics Inc
8.8 Transgenomic Inc.
8.9 Applied Biosystems Inc.,
8.10 PerkinElmer Inc
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
